BioSight
Companies
Aquestive Therapeutics, Inc. logo

AQST

NASDAQWARREN, NJ
Aquestive Therapeutics, Inc.

Aquestive Therapeutics develops pharmaceutical products using proprietary drug delivery technologies, with a focus on central nervous system conditions including epilepsy, ADHD, and ALS. The firm operates across multiple development stages, from marketed products to clinical-stage candidates, and has licensed assets from partners including Assertio Holdings and Sunovion. Aquestive finances operations through debt and equity offerings, including recent underwritten public offerings in 2024 and 2025.

Price history not yet available for AQST.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar